Quarterly Report • Oct 24, 2018
Quarterly Report
Open in ViewerOpens in native device viewer
(Figures in parentheses and comparative figures in the text refer to the corresponding period of last year. The comparative figures in the balance sheet refer to 31 December 2017).
"The third quarter of 2018 was yet another strong quarter with growth of 18% (10% after foreign exchange effects) compared to the corresponding period last year. The increase was driven by sales of BioGaia Protectis drops as well as by favorable growth for BioGaia Prodentis lozenges. Geographically, growth was strong across all three regions, EMEA, Asia Pacific and the Americas. It is worth noting that sales increased significantly in the USA and the rollout of BioGaia Gastrus tablets continues with good growth. Sales for the past 12-month period totaled SEK 702 million (584), an increase of 20% (19% after foreign exchange effects)" says Sebastian Schröder, Acting Managing Director of BioGaia.
Net sales amounted to SEK 174.7 million (147.7), an increase of 18% (excluding foreign exchange effects, 10%).
Net sales in the Pediatrics segment reached SEK 138.3 million (111.1), an increase of 24%.
Net sales in the Adult Health segment amounted to SEK 36.0 million (35.7), an increase of 1%.
Operating profit amounted to SEK 66.2 million (53.8), an increase of 23%. The company has changed an accounting standard as of 1 January 2018, which means that foreign exchange gains/losses attributable to forward contracts are recognized in operating profit or loss (previously among financial items). These amounted to SEK 5.0 million (0.2). With an unchanged standard, operating profit would have increased by 14%.
Profit after tax was SEK 51.4 million (42.1), an increase of 22%.
Earnings per share totaled SEK 2.97 (2.43). No dilutive effects arose.
Cash flow amounted to SEK 44.3 million (37.9).
At the beginning of July, BioGaia acquired an additional 30% in MetaboGen for SEK 27.8 million. The shareholding in MetaboGen thereby amounts to 92%.
BioGaia's subsidiary MetaboGen's first microorganisms are ready to be used in a safety study.
Net sales amounted to SEK 532.2 million (444.9), an increase of 20% (excluding foreign exchange effects, 16%).
Net sales in the Pediatrics segment reached SEK 438.5 million (354.0), an increase of 24%.
Net sales in the Adult Health segment amounted to SEK 92.6 million (85.2), an increase of 9%.
Operating profit amounted to SEK 202.3 million (171.1). Operating profit, excluding revaluation of the former associate shareholding in MetaboGen, amounted to SEK 195.3 million (171.1), an increase of 14%. The company has changed an accounting standard as of 1 January 2018, which means that foreign exchange gains/losses attributable to forward contracts are recognized in operating profit or loss (previously in financial items). These amounted to SEK -8.7 million (+2.0). With an unchanged standard, operating profit would have increased by 21%.
Profit after tax was SEK 157.3 million (132.2), an increase of 19%. Excluding revaluation of the former associate shareholding in MetaboGen, profit after tax rose 14%.
Earnings per share totaled SEK 9.10 (7.63). No dilutive effects arose.
Cash flow for the period was SEK -49.8 million (-2.0). Cash and cash equivalents at 30 September 2018 amounted to SEK 257.5 million (305.9).
Teleconference: Investors, analysts and the media are invited to take part in a teleconference on the interim report to be held today, 24 October 2018 at 09:30 CET with Acting Managing Director Sebastian Schröder.
To participate in the teleconference, please see https://www.biogaia.com/investors/financial-calendar/ for telephone numbers. The teleconference can also be followed at https://tv.streamfabriken.com/biogaia-q3-2018.
This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the acting Managing Director, on 24 October 2018 at 08:00 CET.
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording shall prevail.
The Managing Director of BioGaia AB hereby presents the interim management report for the period 1 January – 30 September 2018.
The third quarter of 2018 was yet another strong quarter with growth of 18% (10% after foreign exchange effects) compared to the corresponding period last year. The increase was driven by increased sales of BioGaia Protectis drops as well as by favorable growth for BioGaia Prodentis lozenges. Geographically, growth was strong across all three regions, EMEA, Asia Pacific and the Americas. It is worth noting that sales increased significantly in the USA and the rollout of BioGaia Gastrus tablets continues with good growth. Sales for the past 12-month period totaled SEK 702 million (584), an increase of 20% (19% after foreign exchange effects).
Sales in the Pediatrics segment amounted to SEK 138 million, an increase of 24% (15% after foreign exchange effects) compared to the third quarter last year. The increase was driven by strong sales growth for BioGaia Protectis drops in all markets as well as by favorable growth for BioGaia Protectis tablets. As communicated in the previous quarterly report, we foresee lower royalty revenues from Nestlé regarding Growing Up Milk (GUM) next year since they have communicated that they wish to renegotiate the agreement which expires at the end of the year. We now assess that royalty revenues under the new agreement will be SEK 40 million lower compared to 2018. The reason is that Nestlé likes to focus on a fewer number of countries. BioGaia is now free to choose new distributors for GUM for the markets that are no longer covered by Nestlé. Our cooperation with Nestlé remains very good and negotiations are underway relating to additional product sales which are expected to compensate for the decline in royalties over time. Sales of BioGaia Protectis drops to Nestlé in the USA and Australia showed a very strong growth for the nine month period compared to the corresponding period last year.
Sales in the Adult Health segment rose by only 1% (-7% after foreign exchange effects), compared to the third quarter last year, to SEK 36 million. Sales of BioGaia Prodentis lozenges and BioGaia Gastrus tablets showed a strong increase during the quarter. So far, we have launched these products in 25 and 13 countries respectively and the rollout continues. Sales of BioGaia Protectis tablets in the Adult Health segment decreased. This was due to reduced sales to one of our major tablet markets, Finland. The decline was due to aggressive marketing and price pressure from a local competitor. However, our distributor in Finland, Verman, expects a recovery in the fourth quarter and hopes to be able to regain market shares. We are monitoring developments carefully in close collaboration with our distributor. Apart from Finland, sales of BioGaia Protectis tablets in the Adult Health segment increased by 30%. For the latest 12 month period the sales in Adult health amounted to SEK 124 (101) million, an increase of 22% (excluding currency effects 21%).
Operating expenses increased by 29% during the quarter. This increase is mainly attributable to R&D costs where we are making considerable investments, among others in our subsidiaries BioGaia Pharma and MetaboGen, as well as in research projects, clinical studies and product development. We have also increased our investments in marketing activities in several countries including Sweden, Italy and Brazil. All this also results in an increased personnel requirement. We have increased the number of employees by 12 people, of which three people relates to the acquisition of MetaboGen, since the third quarter of last year.
Due to the strong sales growth, operating profit increased, despite the higher expenses, by 23% to SEK 66.2 million. If we exclude the effect of changed accounting standards, operating profit increased by 14% to SEK 61.2 million and the operating margin was 35% (36).
As communicated previously, during the second quarter we acquired additional shares in our former associated company MetaboGen. BioGaia already held 36% of the company. At the beginning of April, BioGaia increased its stake to 62% making us the majority shareholder. Just after the end of the second quarter, we acquired an additional 30% in the company, bringing the shareholding up to 92%. In the third quarter the safety study that includes two of the company's bacteria strains, received ethical approval, and the study could start in October. Future products based on these strains are intended to be used for metabolic diseases such as type 2 diabetes, gestational diabetes and nonalcoholic fatty liver disease. We are now working to integrate MetaboGen's operations with BioGaia as regards administration, research and laboratory work.
During the quarter we launched BioGaia Protectis tablets in Australia (bWellness) and BioGaia Gastrus tablets in Poland (Ewopharma) and Hungary (BG Distribution).
Finally, I would like to extend a warm welcome to Isabelle Ducellier who will take over as Managing Director on 5 November. Isabelle is a member of the Board of BioGaia and we are now working to ensure that she can take her place in the operations in the best possible way.
Sebastian Schröder Acting Managing Director of BioGaia 24 October 2018
Consolidated net sales amounted to SEK 174.7 million (147.7) which is an increase of SEK 27.0 million (18%) (excluding foreign exchange effects 10%) compared to the third quarter of last year.
Sales were driven by growth in the Pediatrics segment where sales increased by 24% (excluding foreign exchange effects, 15%) to SEK 138.3 million. This was mainly due to higher sales of BioGaia Protectis drops which increased in all regions. Sales of BioGaia Protectis tablets in the Pediatrics segment also rose during the quarter.
In the Adult Health segment, sales rose by 1% (excluding foreign exchange effects, -7%) to SEK 36.0 million. This was due to higher sales of BioGaia Prodentis oral health tablets (primarily in Asia Pacific but also in Europe) and increased sales of BioGaia Gastrus tablets (primarily in APAC but also in other markets). Sales of BioGaia Protectis tablets decreased during the quarter. This was due to lower sales in Europe attributable to Finland, which is a major market for Protectis tablets (for further comments – see above under Managing Director's comments), while sales increased in other markets. Sales in the previous year included culture for yoghurt ahead of a launch in Japan. Yoghurt sales in Japan have been lower than expected and culture deliveries have therefore ceased. However, this does not affect royalty payments which are based on minimum sales.
The total gross margin for the quarter was 75% (74%). The gross margin for the Pediatrics segment was 76% (77%). The gross margin for the Adult Health segment was 71% (61%). The increase is mainly explained by a sales increase in Japan where margins are higher.
Operating expenses (selling, administrative and R&D expenses) rose by SEK 14.9 million (29%) compared to the third quarter of last year to SEK 65.9 million. The increase is due to several factors. During the quarter, major marketing activities were carried out in a number of countries (including Italy, Brazil and Sweden). In addition, foreign exchange effects contributed to higher expenses in Japan. Expenses also include a provision for the incentive program of SEK 1.5 million (0.9) (see below under Employees). Furthermore, R&D costs rose due to research projects and a large number of clinical studies now underway as well as expenses of SEK 3.0 million (0.4) for the new subsidiaries BioGaia Pharma and MetaboGen (which have been consolidated in the Group since 6 April 2018).
Other operating expenses/income refer to exchange gains/losses on receivables and liabilities of an operating nature and amounted to SEK 1.5 million (-3.8). The company changed its accounting standard as of 1 January 2018, after which all exchange gains/losses attributable to forward exchange contracts are recognized in other operating expenses/income (previously in financial items). These amounted to SEK 5.0 million (0.2).
Operating profit amounted to SEK 66.2 million (53.8), an increase of 23%. The operating margin was 38% (36%). Excluding the effect of changed accounting standards, operating profit rose 14% to SEK 61.2 million and the operating margin was 35% (36%).
Profit after tax amounted to SEK 51.4 million (42.1) an increase of SEK 9.0 million (22%). The effective tax rate was 22% (22%). The quarter also includes a tax expense attributable to fiscal year 2016 of SEK 1.4 million.
Earnings per share amounted to SEK 2.97 (2.43). No dilutive effects arose during the quarter.
Launches in the third quarter
| Distributor/licensee | Country | Product |
|---|---|---|
| BioGaia Protectis | ||
| tablets with | ||
| Aché | Brazil | strawberry flavor |
| BioGaia Gastrus | ||
| BG Distribution | Hungary | tablets |
| BioGaia Protectis | ||
| tablets with | ||
| bWellness | Australia | strawberry flavor |
| BioGaia Gastrus | ||
| Ewopharma | Poland | tablets |
| BioGaia Protectis | ||
| drops and BioGaia | ||
| Protectis tablets with | ||
| Philips Pharma | Mauritius | lemon flavor |
| BioGaia Protectis | ||
| tablets with vitamin D | ||
| BioGaia Protectis | ||
| tablets with | ||
| Pediact | France | strawberry flavor |
In early April, BioGaia decided to acquire additional shares in the associated company MetaboGen AB and invested SEK 11.7 million in shares in the company. BioGaia's shareholding thus increased from 36% to 62% making BioGaia the majority shareholder.
During the second quarter the set milestones were achieved, which related to new agreements with the University of Gothenburg and Chalmers University of Technology. These agreements will give BioGaia and MetaboGen more extensive and closer cooperation with the universities. At the beginning of July, BioGaia therefore acquired a further 30% of the shares in MetaboGen for SEK 27.8 million. The higher valuation of the shares, compared to the deal in April, is attributable to the new agreements. The shareholding thereby amounted to 92%. BioGaia will acquire the remaining 8% in the company within a three-year period. The additional purchase price can amount to a maximum of SEK 12 million depending on how many milestones are achieved.
Research on the microbiome is developing very rapidly and pharmaceutical companies are making major investments in this area. Through the investment in MetaboGen, BioGaia can maintain its strong position in the field of probiotic research. BioGaia will initiate a number of research projects in MetaboGen. The cost of these projects is estimated at around SEK 22 million and the projects will be implemented over a three-year period starting in the third quarter of 2018. In addition, operations and developments that are already taking place in the company today are estimated to cost approximately SEK 10 million per year, if no license agreements with third parties are made. The base for the company's business model is to find licensees.
BioGaia's subsidiary MetaboGen has achieved a key development goal. The first version of the next generation's probiotics is ready to be used in a safety study.
Two strains, Faecalibacterium prausnitzii (DSM 32379) and Desulfovibrio piger (DSM 32187), derived from the human gut microbiome, have been chosen in this project. Because of the oxygen sensitive properties of the strains, MetaboGen has developed, and patented, a unique production technology, allowing the bacteria to survive in a commercial product. This has been a crucial step in the product development and one that may also potentially be suitable for other similar strains.
The two selected strains have been thoroughly examined regarding properties, safety and antibiotic resistance. The strains have been produced and the product formulation successfully completed. The first version of the product is thereby ready to be used. Recently the ethical application for the first human safety trial was approved and the clinical study started in October.
Future products based on these strains aim to be used in the management of metabolic diseases, such as type 2 diabetes, gestational diabetes and non-alcoholic fatty liver disease.
Consolidated net sales amounted to SEK 532.2 million (444.9) which is an increase of SEK 87.3 million (20%) (excluding foreign exchange effects, 16%) compared to the corresponding period last year. For the past 12-month period, sales totaled SEK 702.4 million (583.6), an increase of 20% (excluding foreign exchange effects, 19%).
Sales in the Pediatrics segment amounted to SEK 438.5 million (354.0) an increase of SEK 84.5 million (24%) (excluding foreign exchange effects, 21%). The increase was driven mainly by sales of BioGaia Protectis drops. For the past 12-month period, sales in the Pediatrics segment rose by 22% (excluding foreign exchange effects, 20%).
Sales of drops, which make up the bulk of sales, increased in all regions - in EMEA (in most countries but primarily in Eastern European countries, Italy, Turkey, France and Spain), in the Americas (primarily the USA) and in Asia Pacific (primarily China but also Indonesia and India). The highly positive sales trend for drops continued over the past 12-month period.
Sales of BioGaia Protectis tablets in the Pediatrics segment increased compared to the corresponding period last year, particularly in EMEA (primarily the Eastern European countries and Spain) but also in Asia Pacific (primarily Taiwan) while sales in the Americas decreased slightly. For the past 12-month period, sales growth for tablets in the Pediatrics segment was good.
Royalty revenue from the sale of growing up milk with Lactobacillus reuteri Protectis for children over the age of one increased compared with the corresponding period last year. For the past 12-month period, the increase in revenue was good. As mentioned above, BioGaia's royalty agreement with Nestlé expires at the end of the year. Nestlé has communicated that they wish to renegotiate the royalty agreement. The company assesses that this will lead to a reduction in royalty revenues of approximately SEK 40 million compared with 2018. For further comments, please see above under Managing Director´s comments.
Sales of culture, at low margins, for use in Nestlé's infant formula decreased compared to the corresponding period last year and for the past 12-month period.
Royalty revenue from the collaboration agreement with Nestlé amounted to SEK 7.2 million (11.4). The collaboration agreement with Nestlé was signed in March 2014. Royalty revenue totaling SEK 91.8 million has been divided between the Pediatrics segment and Other Sales over the period 2014- 2018. Up to 30 September 2018, BioGaia has recognized SEK 88.9 million of this revenue, of which SEK 42.2 million in Other Sales and SEK 46.7 million in the Pediatrics segment. The remaining revenue of SEK 2.9 million will be recognized as revenue in the Pediatrics segment during 2018.
Net sales in the Adult Health segment amounted to SEK 92.6 million (85.2), an increase of SEK 7.4 million (9%) (excluding foreign exchange effects, 5%) compared to the corresponding period of last year. Revenue in the previous year included compensation from the agreement with Kabaya Ohayo in Japan, for knowhow, education and preparations for the launch. Adjusted for this revenue, sales were up by 19%. For the past 12-month period, sales in the Adult Health segment rose by 22% (excluding foreign exchange effects, 21%).
Sales growth was driven by oral health products which increased substantially compared to the corresponding period of last year. Sales increased in Asia Pacific (Japan) and in EMEA (several countries). No oral health products are sold in the Americas at present. The company is making active efforts to find additional distribution partners for the products. Development has been very positive over the past 12-month period.
Sales of BioGaia Protectis tablets decreased compared to the corresponding period of last year. Sales increased in Asia Pacific (primarily Japan but also Hong Kong) while declining sharply in EMEA (Finland) – for comments see the Managing Director's comments above. In Sweden and Italy, on the other hand, sales increased. In the Americas, sales of tablets were unchanged but remain at a low level.
For the past 12-month period, sales development has been very favorable for Asia Pacific but has decreased in Europe due to the decline in Finland.
Sales of BioGaia Gastrus tablets remain at a low level but rose sharply compared to the corresponding period of last year. Sales increased in all regions in countries such as the USA, Japan, Spain, China and Hong Kong. The company is making active efforts to find additional distribution partners for this product. Development in the past 12-month period was good.
Other sales amounted to SEK 1.1 million (5.7), a decrease of SEK 4.6 million (81%). No foreign exchange effects arose. Other Sales included royalty revenue of SEK 0 million (3.5) from the collaboration agreement with Nestlé (see above under Pediatrics).
Sales in EMEA amounted to SEK 318.6 million (278.5), an increase of 14%. The increase was attributable to the Pediatrics segment. For the past 12 month period, sales rose by 17%.
Sales in Asia Pacific amounted to SEK 84.3 million (60.2), an increase of 40%. The increase was mainly attributable to the Pediatrics segment but Adult Health sales also rose. For the past 12-month period, sales increased by 62%.
In the Americas, sales amounted to SEK 129.4 million (106.1), an increase of 22%. The increase was mainly attributable to the Pediatrics segment. For the past 12-month period, sales increased by 8%.
Of total finished consumer products (drops, gut health tablets, oral health tablets, oral rehydration solution, etc.) sold during the period January - September 2018, 68% (69%) were sold under the BioGaia brand, including co-branding.
Total gross margin was unchanged at 75% (75%).
Gross margin for Pediatrics was unchanged at 76% (76%).
Gross margin for the Adult Health segment was 71% (66%). The increase is mainly due to higher sales in Japan where the margin is higher than in other markets.
Operating expenses (selling, administrative and R&D expenses) amounted to SEK 197.5 million (155.5), an increase of 27%. During the period major marketing activities were carried out in a number of countries (including Italy, Brazil and Sweden). In addition, personnel expenses increased due to a higher number of employees and a one-time expense of SEK 3.1 million for the outgoing Managing Director. Expenses also include a provision for the incentive program of SEK 6.5 million (2.6) (see below under Employees). Furthermore, R&D costs increased due to research projects and a large number of ongoing clinical studies.
In addition, the Group includes two new companies since last year, BioGaia Pharma AB and MetaboGen AB. Expenses for these companies amount to SEK 6.1 million (0.4).
Other operating expenses/income refer to exchange gains/losses on receivables and liabilities of an operating nature. These amounted to SEK -5.0 million (-4.5). The Group has changed its accounting standard (see below under New accounting standards) and with effect from 2018 (and including comparative figures for the previous year) reports exchange gains/losses on forward exchange contracts in operating profit or loss since the assessment is that they are attributable to operations. Other operating expenses/income include an exchange loss/gain relating to forward exchange contracts of SEK -8.7 million (+2.0). At 30 September 2018, the company had outstanding forward contracts for EUR 15.1 million at an average exchange rate of SEK 9.88 and for USD 9.2 million at an average exchange rate of SEK 8.18. The actual exchange loss/gain depends on the exchange rate on the maturity date of the contracts.
MetaboGen was an associated company in BioGaia until 6 April 2018. The share of profits of associates refers to BioGaia's share (36%) of MetaboGen AB's profits up to 6 April 2018 and amounted to SEK -0.5 million (-1.2).
Operating profit amounted to SEK 202.3 million (171.1), an increase of 18%. Operating profit, excluding revaluation of the former associate shareholding in MetaboGen, amounted to SEK 195.3 million (171.1), an increase of SEK 24.2 million (14%) after a change of accounting standard (see below under New accounting standard). Operating margin was 37% (38%). With an unchanged accounting standard, operating profit would have amounted to SEK 203.9 million (169.1), an increase of 21% with an operating margin of 38% (38%).
In a step acquisition, all previous equity interests in the acquiree are adjusted to fair value and all gains and losses thus arising are recognized in profit or loss. As a result of this, a gain of SEK 7.0 million is recognized in operating profit regarding the previous associate shareholding in MetaboGen. Since BioGaia increased its holding to 62% and thereby obtained a controlling interest in MetaboGen, the company is consolidated as a subsidiary as of 6 April 2018.
Profit after tax was SEK 157.3 million (132.2), an increase of SEK 25.1 million (19%). Excluding revaluation of the former associate shareholding in MetaboGen, profit after tax increased by 14%. The effective tax rate for the Group was 22% (23%).
Owing to the distribution and license agreement that was signed in Japan at the end of 2016 (see annual reports for 2016 and 2017), it will be possible to utilize a large share of the earlier loss carryforward in Japan in the Japanese company. In the Group, the exclusivity fees for product rights will be recognized successively over the term of the agreement and a deferred tax asset was therefore recognized in 2016. At 30 September 2018, the deferred tax asset amounted to SEK 8.6 million (9.3). The Group thus has no loss carryforwards for which deferred tax is recognized.
Earnings per share amounted to SEK 9.10 (7.63). No dilutive effects arose during the period.
Total assets amounted to SEK 598.1 million (576.1). During the period cash and cash equivalents and equity decreased as a result of dividends, see below under Cash flow, while inventories and trade receivables increased. The increase is due to higher sales. Furthermore, a surplus value due to the acquisition of MetaboGen increased total assets by SEK 52.2 million.
Cash flow amounted to SEK -49.8 million (-1.9). Cash flow includes dividends of SEK 158.7 million (130.0), as well as the net investment in MetaboGen of SEK 33.9 million (0). Cash and cash equivalents at 30 September 2018 amounted to SEK 257.5 million (305.9).
Investments in property, plant and equipment amounted to SEK 10.6 million (25.1) of which the majority relates to the subsidiary BioGaia Production.
Net sales in the Parent Company amounted to SEK 500.6 million (427.2) and profit before tax was SEK 169.6 million (152.5). The figure for the previous year included the reversal of a previously impaired receivable on a loan to the subsidiary in Japan of SEK 23.3 million since the subsidiary repaid part of the loan in the first quarter of 2017. Cash flow amounted to SEK -62.4 million (2.7).
Net sales in the Japanese subsidiary amounted to SEK 41.6 million (26.7) during the period. Operating profit for the Japanese operations amounted to SEK 8.1 million (4.2). The figure for the previous year included compensation for knowhow, etc. (see above under the Adult Health segment) from the agreement with Kabaya Ohayo.
BioGaia Production is a wholly owned subsidiary of BioGaia that manufactures the company's products, primarily drops.
Net sales amounted to SEK 81.1 million (59.2). Operating profit amounted to SEK 29.2 million (19.4).
CapAble is owned 90.1% by BioGaia and 9.9% by CapAble's Managing Director. Net sales in CapAble amounted to SEK 1.0 million (1.8). Operating result was SEK -1.2 million (-0.5).
In June 2017, BioGaia announced that the company had established a subsidiary, BioGaia Pharma, to take advantage of the opportunities to develop drugs identified in the R&D activities conducted as part of the company's normal operations. BioGaia Pharma is owned 96% by BioGaia and 4% by the company's Managing Director. The company has no revenues. Operating profit for the period amounted to SEK -3.8 million (-0.4). The company has received shareholder contributions of SEK 6.0 million from the Parent Company, of which SEK 4.0 million in the period January-September 2018.
MetaboGen is a research-driven company that was founded in 2011 in Gothenburg. The company's founders include Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B. Nielsen at Chalmers University of Technology. These researchers still work with the company. MetaboGen conducts research in the microbiome area including sequencing of all genes in the microflora, for example in the human intestine, to find previously unknown components and patterns in the microbial diversity and link this to health and disease.
Since the beginning of April, BioGaia owned 62% of the company (see above). During the second quarter the set milestones were achieved, which related to new agreements with the University of Gothenburg and Chalmers University of Technology. These agreements will give BioGaia and MetaboGen more extensive and closer cooperation with the universities. At the beginning of July, BioGaia therefore acquired additional shares for SEK 27.8 million, after which BioGaia's holding amounts to 92%.
Operating profit for MetaboGen starting from 6 April 2018, amounted to SEK -2.4 million.
The number of employees in the Group at 30 September 2018 was 127 (120). The company has an incentive program for all employees based on the company's sales and profits. The maximum bonus amounts to 12% of salary. One-third of the bonus relates to a long-term incentive program where the employee is required to reinvest the yearly paid-out compensation (after tax) in BioGaia class B shares and hold these for at least three years. The company made provisions to a reserve for the costs of the incentive program of SEK 6.5 million (2.6) for the period January-September 2018.
BioGaia's goal is to create strong value growth and a good return for the shareholders. This will be achieved through a greater emphasis on the BioGaia brand, increased sales to both existing and new customers and a controlled cost level.
The long-term financial target is an operating margin (operating profit in relation to sales) of at least 34% with continued strong growth and increased investments in research, product development, brand building and the sales organization.
BioGaia's dividend policy is to pay a shareholder dividend equal to 40% of profit after tax.
In view of the company's strong portfolio consisting of an increased number of innovative products that are sold predominantly under the BioGaia brand, successful clinical trials and an expanding distribution network that covers a large share of the key markets, BioGaia's future outlook remains bright.
Significant risks and uncertainties are described in the administration report of the annual report for 2017, on pages 40 and 41 and in Notes 28 and 29. No significant changes in these risks and uncertainties are assessed to have taken place at 30 September 2018.
This interim management statement has in all material respects been prepared in accordance with Nasdaq OMX Stockholm's Guidelines for preparing interim management statements. Disclosures in accordance with IAS 34 Interim Financial Reporting are provided both in notes and elsewhere in the interim report. The consolidated financial statements have been prepared in compliance with the accounting policies applied in preparation of the most recent annual report with the addition of new accounting standards as set out below.
The financial statements and segment information correspond to the presentation used in the interim reports prepared in accordance with IAS 34 in order to achieve comparability in the presentation between the quarters. The interim report also includes Managing Director's comments although this is not a requirement according to Nasdaq Stockholm's Guidelines for preparing interim management statements. This information is still judged important to meet user requirements.
The accounting standards applied concur with those set out in the 2017 Annual Report with the exception of those applying to "Financial instruments" (IFRS 9 replaces IAS 39) and "Revenue from Contracts with customers" (IFRS 15 replaces IAS 18 and IAS 11).
The Group has reviewed its financial assets and liabilities and assessed that the effects of IFRS 9 on the consolidated financial statements at 1 January 2018 amounts to SEK 0.3 million. According to IFRS 9 entities shall recognize a reserve that corresponds to expected credit losses within the next 12 months. This means that BioGaia's trade receivables are written down at initial application of IFRS 9. In assessment of the credit risk, incurred credit losses and an adjustment for expected future losses provide the basis for the reserve. BioGaia has no incurred credit losses. Default rate shall be evaluated each quarter.
The adjustment relates to a reserve for uncertainty in trade receivables and has been recognized in changes in equity. At 30 September 2018 the reserve amounted to SEK 0.3 million. The difference compared to 1 January 2018 is recognized in profit or loss. The Group has also changed policy from recognition of all derivatives in net financial items to recognition based on the item they hedge. Changes in value in relation to operating receivables, liabilities and derivatives are recognized in operating profit or loss while changes in value of financial receivables, liabilities and derivatives are recognized in net financial items. Forward contract hedges are recognized at fair value through profit or loss in accordance with the items they hedge. This means the company's exchange gains and losses relating to forward exchange contracts are recognized in operations with effect from 1 January 2018.
New accounting standards for financial instruments are provided below.
Financial instruments recognized in the statement of financial position include on the assets side cash and cash equivalents, trade receivables, other current receivables and currency derivatives to the extent these have a positive fair value. On the liabilities side, there are trade payables, other current liabilities, loans and currency derivatives to the extent these have a negative fair value. The category to which the Group's financial assets and liabilities belong is specified in the note Financial assets and liabilities – classification and measurement of fair value.
A financial asset or liability is recognized in the statement of financial position when the company become party to the contractual terms of the instrument. A receivable, except trade receivables, is recognized when the company has performed and a contractual obligation exists for the counterparty to pay, even if no invoice has yet been sent. Trade receivables are recognized in the statement of financial position when an invoice has been sent. Liabilities, except trade payables, are recognized when the counterparty has performed and a contractual obligation to pay exists, even if an invoice has not yet been received. Trade payables are taken up when an invoice is received. A financial asset is derecognized from the statement of financial position when the contractual rights are realized, expire or the company has relinquished control. The same applies to part of a financial asset. A financial liability is derecognized from the statement of financial position when the contractual obligations are met or otherwise extinguished. The same applies to part of a financial liability. No currency derivatives or other financial assets and liabilities are offset in the statement of financial position since the terms for offsetting are not met. Acquisition and disposal of financial assets are recognized on the transaction date. The transaction date is the day the company undertakes to acquire or dispose of the asset.
Financial assets are classified on the basis of the business model in which the asset is held and its cash flow characteristic. If the financial asset is held within the framework of a business model whose objective is collecting contractual cash flows and the financial assets at identified dates gives rise to cash flows that are solely payments of principal and interest on the principal, the asset is recognized at amortized cost.
If the financial asset is held in a business model whose objective can be achieved both by collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise to cash flows that are solely payments of principal and interest on the principal at identified dates, the asset is recognized at fair value through other comprehensive income.
All other business models where the purpose is speculation, held for trading or where the cash flow characteristic excludes other business models result in recognition at fair value through profit or loss.
Amortized cost for a financial asset is the amount at which the financial asset is measured at initial recognition minus principal repayments, plus the cumulative amortization using the effective interest method of any difference between that principal and the outstanding
principal, adjusted for any impairment. The gross carrying amount of a financial asset is the amortized cost of a financial asset before adjustment for any loss allowance.
Financial liabilities are recognized at amortized cost using the effective interest method or at fair value through profit or loss.
Loans and other financial liabilities, e.g. trade payables, are included in this category. Liabilities are measured at amortized cost.
Financial liabilities at fair value through profit or loss This category consists of financial liabilities held for trading. This category includes the Group's derivatives with negative fair value.
Effective from 1 January 2018 the Group recognizes a loss allowance for expected credit losses on a financial asset measured at amortized cost or fair value through other comprehensive income, for a lease receivable or for a contract receivable. At each closing date, the Group shall recognize in profit or loss the change in expected credit losses since the initial recognition date.
For trade receivables, contract assets and lease receivables there is a simplified model which mean that the Group recognizes directly expected credit losses for the remaining term of the assets. The expected credit losses for these financial assets are calculated with the aid of a provision matrix which is based on historical events, current conditions and forecasts for future economic conditions and the time value of the money if applicable. For all other financial assets the Group shall measure a loss allowance to an amount that corresponds to 12 months' expected credit losses. For financial instruments for which significant increase in credit risk has occurred since the initial recognition date, an allowance is recognized based on credit losses for the entire term to maturity of the asset. Equity instruments are not subject to these impairment rules.
BioGaia has conducted a review of the Group's current policies for revenue recognition and compared these with IFRS 15. IFRS 15 means that revenue is recognized when control is transferred to a purchaser compared with the current method that is based on risks and rewards. The analysis of the introduction of IFRS 15 has been based on a detailed review of BioGaia's revenue streams. BioGaia has chosen to apply the modified retrospective method for transfer to IFRS 15. According to IFRS 15 this means that BioGaia recognized the combined effect of initial application of this standard as an adjustment to the opening balance of retained earnings for the financial year that includes the initial date of application, i.e. 1 January 2018 for BioGaia. This means that IFRS 15 is only applied retrospectively for contracts that are not completed at 1 January 2018. BioGaia has chosen to apply this practical solution to all contract changes that take place before the date of initial application (i.e. 1 January 2018) to not retroactively recalculate the contract for these contract changes.
After its completed analysis, BioGaia assesses that the effect on the consolidated financial statements will not have an impact on BioGaia's consolidated financial statements for 2018.
IFRS 15 includes a new model for revenue recognition (the five-step model) that is based on when control of a good or service is transferred to the customer. The basic principle is that an entity recognizes revenue to differentiate between the transfer of promised goods or services to customers and an amount that reflects the compensation to which the entity is expected to be entitled in exchange for such goods or services.
Step 1. Identify the contract with a customer
Steg 2. Identify the performance obligations in the contract Steg 3. Determine the transaction price
Steg 4. Allocate the transaction price to each performance obligation
Steg 5. Recognize revenue when a performance obligation is satisfied
Revenue is recognized on the basis of the amount specified in a contract with a customer and does not include any amounts received on account of a third party. BioGaia recognizes revenue when the Group transfers control of a product or service to a customer. Details of these new requirements and BioGaia's revenue streams are provided below.
BioGaia's revenues mainly comprise sales of goods. No commitment for BioGaia remains after delivery since BioGaia does not provide customers with any extended guarantees or the option to return. Control is transferred to the customer when the good is placed at the disposal of the purchaser. In addition to the sales of goods the other revenue consists of royalties or exclusivity rights linked to product distribution in a defined market/territory. These contracts include obligations over time and revenue is recognized in pace with fulfilment of BioGaia's performance obligations. The transaction price, i.e. the compensation BioGaia expects to receive in exchange for the goods and services is in most cases fixed and therefore easy to determine. Variable compensation exists in individual cases often in combination with minimum levels relating to compensation which simplifies assessment of the transaction price. In summary, the transfer to IFRS 15 will result in no change in BioGaia's accounting as regards the timing of revenue recognition
IFRS 16 is effective from 1 January 2019. The company has started a review of existing leasing agreement. The company's assessment is that this will not have a material effect on the company's earnings and financial position.
Most of the company's sales are denominated in foreign currency, primarily EUR but also USD and JPY. With unchanged exchange rates, compared with the corresponding period last year, net sales would have been SEK 15.0 million lower for the nine-month period. Exchange rate differences affect both revenues and expenses.
| (Amounts in SEK 000s) | Jan-Sept | Jan Sept |
July Sept |
July-Sept | Jan-Dec | Oct 2017- | Oct 2016- |
|---|---|---|---|---|---|---|---|
| 2018 | 2017 | 2018 | 2017 | 2017 | Sept 2018 |
Sept 2017 |
|
| Net sales (Note 1) | 532,197 | 444,855 | 174,673 | 147,676 | 615,003 | 702,345 | 583,605 |
| Cost of sales | -133,864 | - 112,625 |
-44,096 | -38,853 | -151,655 | -172,894 | -147,323 |
| Gross profit | 398,333 | 332,230 | 130,577 | 108,823 | 463,348 | 529,451 | 436,282 |
| Selling expenses | -106,850 | -87,466 | -34,522 | -28,334 | -127,115 | -146,499 | -121,279 |
| Administrative expenses | -20,767 | -16,032 | -6,187 | -5,154 | -22,063 | -26,798 | -21,252 |
| Research and development expenses | -69,920 | -51,957 | -25,164 | -17,490 | -75,700 | -93,663 | -70,082 |
| Share of profit of associates | -500 | -1,200 | - | -200 | -820 | -120 | -1,984 |
| Revaluation of former associate shareholding (Note 2) |
7,004 | - | - | - | - | 7,004 | - |
| Other operating income/expenses | -5,049 | -4,473 | 1,487 | -3,818 | -4,659 | -5,235 | -3,327 |
| Operating profit | 202,251 | 171,102 | 66,191 | 53,827 | 232,991 | 264,140 | 218,358 |
| Interest income | 274 | - | 0 | - | 112 | 386 | 65 |
| Financial expenses | -201 | -154 | 204 | -24 | -192 | -239 | -146 |
| Profit before tax | 202,324 | 170,948 | 66,395 | 53,803 | 232,911 | 264,287 | 218,277 |
| Deferred tax | -693 | - | 0 | - | -1,094 | -1,787 | 10,433 |
| Tax expense | -44,351 | -38,736 | -15,023 | -11,657 | -51,253 | -56,868 | -49,523 |
| PROFIT FOR THE PERIOD | 157,280 | 132,212 | 51,372 | 42,146 | 180,564 | 205,632 | 179,187 |
| Items that may be subsequently reclassified to profit or loss |
|||||||
| Gains/losses arising on translation of the | |||||||
| statements of foreign operations | -272 | 854 | 46 | 421 | 565 | ||
| Comprehensive income for the period | 157,008 | 133,066 | 51,418 | 42,567 | 181,129 |
| Profit for the period attributable to: | |||||
|---|---|---|---|---|---|
| Owners of the Parent Company | 157,842 | 132,212 | 51,455 | 42,146 | 180,564 |
| Non-controlling interests | -562 | 0 | -83 | 0 | 0 |
| Comprehensive income for the period attributable to: |
157,280 | 132,212 | 51,372 | 42,146 | 180,564 |
| Owners of the Parent Company | 157,570 | 133,066 | 51,501 | 42,567 | 181,129 |
| Non-controlling interests | -562 | 0 | -83 | 0 | 0 |
| 157,008 | 133,066 | 51,418 | 42,567 | 181,129 | |
| Earnings per share | |||||
| Earnings per share (SEK) | 9.10 | 7.63 | 2.97 | 2.43 | 10.42 |
| Number of shares (thousands) | 17,336 | 17,336 | 17,336 | 17,336 | 17,336 |
| Average number of shares (thousands) | 17,336 | 17,336 | 17,336 | 17,336 | 17,336 |
| CONSOLIDATED BALANCE SHEETS | 30 Sept | 31 Dec | 30 Sept |
|---|---|---|---|
| Summary (amounts in SEK 000s) | 2018 | 2017 | 2017 |
| ASSETS Property, plant and equipment Intangible assets (Note 2) Shares in associates Deferred tax asset |
104,963 52,242 - 8,646 |
102,465 - 9,932 9,339 |
103,061 - 9,552 10,010 |
| Other non-current receivables | 43 | 39 | 39 |
| Total non-current assets | 165,894 | 121,775 | 122,662 |
| Current assets excl. cash and cash equivalents Cash and cash equivalents |
174,713 257,491 |
148,481 305,856 |
160,014 240,154 |
| Total current assets | 432,204 | 454,337 | 400,168 |
| TOTAL ASSETS | 598,098 | 576,112 | 522,830 |
| EQUITY AND LIABILITIES | |||
| Equity attributable to owners of the Parent Company Non-controlling interests |
447,849 3,234 |
463,904 -16 |
418,239 -16 |
| Total equity (note 3) | 451,083 | 463,888 | 418,223 |
| Provision for deferred tax Current liabilities |
7,633 139,382 |
778 111,446 |
332 104,275 |
TOTAL LIABILITIES AND EQUITY 598,098 576,112 522,830
Other current liabilities include forward exchange contracts with a fair value of SEK 9.6 million. All forward exchange contracts are attributable to level 2 of the fair value hierarchy. The fair values of other receivables, cash and cash equivalents, trade payables and other liabilities are estimated to be equal to their carrying amounts (amortized cost) due to the short maturity.
| CONSOLIDATED CASH FLOW | July | ||||
|---|---|---|---|---|---|
| STATEMENTS | Jan-Sept | Jan-Sept | Sept | July-Sept | Jan-Dec |
| Summary (amounts in SEK 000s) | 2018 | 2017 | 2018 | 2017 | 2017 |
| Operating activities | |||||
| Operating profit Depreciation/amortization Unrealized gains/losses on forward exchange |
202,251 5,615 |
171,102 4,377 |
66,191 1,880 |
53,827 1,608 |
232,991 6,573 |
| contracts | 8,679 | -1,983 | -4,966 | -195 | 842 |
| Revaluation of former associate shareholding in MetaboGen Other non-cash items |
-7,004 -556 |
- 2,245 |
- 1,958 |
- 620 |
- 1,716 |
| 208,985 | 175,741 | 65,063 | 55,860 | 242,122 | |
| Paid tax | -38,336 | -37,160 | -12,803 | -12,386 | -49,547 |
| Interest received and paid | 72 | -155 | 204 | -24 | -157 |
| Cash flow from operating activities before changes in working capital |
170,721 | 138,426 | 52,464 | 43,450 | 192,418 |
| Changes in working capital | -17,305 | 14,759 | 22,195 | 97 | 30,197 |
| Cash flow from operating activities | 153,416 | 153,185 | 74,659 | 43,547 | 222,615 |
| Acquisition of property, plant and equipment | -10,581 | -25,126 | -2,537 | -5,694 | -26,624 |
| Acquisition of subsidiary | -33,922 | - | -27,835 | - | - |
| Reduction of non-current receivables | - | - | - | - | -19 |
| Cash flow from investing activities | -44,503 | -25,126 | -30,372 | -5,694 | -26,643 |
| Dividends | -156,028 | -130,023 | - | - | -130,023 |
| Provision to the Foundation to Prevent Antibiotic Resistance |
-2,700 | - | - | - | -2,400 |
| Formation of BioGaia Pharma | - | - | - | - | 2 |
| Cash flow from financing activities | -158,728 | -130,023 | 0 | 0 | -132,421 |
| Cash flow for the period Cash and cash equivalents at beginning of |
-49,815 | -1,964 | 44,287 | 37,853 | 63,551 |
| period Exchange differences in cash and cash |
305,856 | 243,069 | 215,477 | 202,582 | 243,069 |
| equivalents | 1,450 | -951 | -2,273 | -281 | -764 |
| Cash and cash equivalents at end of period | 257,491 | 240,154 | 257,491 | 240,154 | 305,856 |
The Executive Management has analyzed the Group's internal reporting system and established that the Group's operations are governed and evaluated based on the following segments:
For the above segments BioGaia reports revenue and gross profit, which are monitored regularly by the Managing Director (who is regarded as the chief operating decision maker) together with the Executive Management. There is no monitoring of the company's total assets against the segments' assets.
| Jan-Sept | Jan Sept |
July Sept |
July Sept |
Jan Dec |
Oct 2017- |
Oct 2016- |
|
|---|---|---|---|---|---|---|---|
| Sept | Sept | ||||||
| Revenue by segment (SEK 000s) | 2018 | 2017 | 2018 | 2016 | 2017 | 2018 | 2017 |
| Pediatrics Adult Health |
438,476 92,577 |
353,960 85,179 |
138,255 36,041 |
111,118 35,652 |
492,550 116,176 |
577,066 123,574 |
473,196 101,059 |
| Other | 1,144 | 5,716 | 377 | 906 | 6,277 | 1,705 | 9,350 |
| Total | 532,197 | 444,855 | 174,673 | 147,676 | 615,003 | 702,345 | 583,605 |
| Gross profit by segment | |||||||
| Pediatrics | 331,919 | 270,437 | 104,594 | 86,097 | 378,936 | 440,418 | 362,247 |
| Adult Health Other |
65,436 978 |
56,077 5,716 |
25,759 224 |
21,820 906 |
78,173 6,239 |
87,532 1,501 |
64,719 9,316 |
| Total | 398,333 | 332,230 | 130,577 | 108,823 | 463,348 | 529,451 | 436,282 |
| Selling, administrative and R&D | - | - | |||||
| expenses | -197,537 | 155,455 | -65,873 | -50,978 | 224,878 | ||
| Share of profits of associates Revaluation of former associate |
-500 | -1,200 | - | -200 | -820 | ||
| shareholding | 7,004 | - | - | - | - | ||
| Other operating expenses | -5,049 | -4,473 | 1,487 | -3,818 | -4,659 | ||
| Operating profit | 202,251 | 171,102 | 66,191 | 53,827 | 232,991 | ||
| Net financial items | 73 | -154 | 204 | -24 | -80 | ||
| Profit before tax | 202,324 | 170,948 | 66,395 | 53,803 | 232,911 | ||
| Asia Pacific | |||||||
| Pediatrics | 32,289 | 16,417 | 11,741 | 4,706 | 31,237 | ||
| Adult Health | 51,806 | 43,586 | 24,541 | 17,872 | 63,992 | ||
| Other | 172 | 246 | 74 | 20 | 246 | ||
| Total Asia Pacific | 84,267 | 60,249 | 36,356 | 22,598 | 95,475 | ||
| EMEA | |||||||
| Pediatrics | 280,862 | 234,599 | 86,708 | 69,294 | 338,716 | ||
| Adult Health | 36,751 | 39,036 | 10,046 | 16,461 | 49,395 | ||
| Other | 966 | 4,860 | 303 | 494 | 5,359 | ||
| Total EMEA | 318,579 | 278,495 | 97,057 | 86,249 | 393,470 | ||
| Americas | |||||||
| Pediatrics | 125,325 | 102,944 | 39,806 | 37,118 | 122,597 | ||
| Adult Health | 4,020 | 2,557 | 1,454 | 1,319 | 2,789 | ||
| Other | 6 | 610 | 0 | 392 | 672 | ||
| Total Americas | 129,351 | 106,111 | 41,260 | 38,829 | 126,058 | ||
| Total | 532,197 | 444,855 | 174,673 | 147,676 | 615,003 | ||
| Date of recognition | |||||||
| Performance obligations met on specific date (Product sales) Performance obligations met over time |
477,645 | 381,429 | 156,878 | 131,028 | 522,093 | ||
| (Royalties) | 54,552 | 63,426 | 17,795 | 16,648 | 92,910 | ||
| Total | 532,197 | 444,855 | 174,673 | 147,676 | 615,003 |
On 6 April 2018, BioGaia acquired 26% of MetaboGen AB for SEK 11.7 million. The purchase consideration was paid in cash. BioGaia already held 36% of the company and recognized it as an associated company. In a step acquisition, all previous equity interests in the acquiree are adjusted to fair value and all gains and losses thus arising are recognized in profit or loss. As a result of this, a gain of SEK 7.0 million is recognized in operating profit regarding the previous associate shareholding in MetaboGen. Since BioGaia increased its holding to 62% and thereby obtained a controlling interest in MetaboGen, the company is consolidated as a subsidiary as of 6 April 2018.
There were no contractual obligations for additional purchase considerations, but an agreement was signed to acquire the remaining shares in MetaboGen in two steps. During the second quarter the set milestones were achieved, which related to new agreements with the University of Gothenburg and Chalmers University of Technology. These agreements will give BioGaia and MetaboGen more extensive and closer cooperation with the universities. At the beginning of July, BioGaia therefore acquired a further 30% of the company for SEK 27.8 million. This has been recognized in equity as a transaction between owners with an effect on Equity attributable to owners of the Parent Company of SEK -14.6 million, as a result of a higher valuation of the acquisition of the further 30% of MetaboGen´s shares.
BioGaia will also acquire the remaining 8% of the company within a three-year period. The additional purchase consideration can amount to a maximum of SEK 12 million depending on the number of milestones achieved.
MetaboGen was founded in 2011 by Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B. Nielsen at Chalmers University of Technology, together with GU Ventures, which commercializes research results and develops companies with ties to the University of Gothenburg. The company is domiciled in Gothenburg, Sweden. Aside from assignments for BioGaia, MetaboGen collaborates with the pharmaceutical company Ferring and holds a number of patents and patent applications in the microbiome area. The company has a laboratory in Gothenburg where development of new probiotic strains takes place.
Research on the microbiome is advancing very rapidly and pharmaceutical companies are making major investments in this area. Through the investment in MetaboGen, BioGaia will be able to maintain its strong position in the field of probiotic research.
| 364 |
|---|
| 261 |
| 5,600 |
| -6,426 |
| -201 |
| -17,062 |
| -16,436 |
| 52,242 |
| -6,855 |
| 11,688 |
The acquisition was carried out on 6 April 2018 and the acquired company has contributed net sales of SEK 0 million and a net loss of SEK 2.4 million. If the acquisition had taken place on 1 January 2018, management's assessment is that during the period 1 January – 30 September 2018 the acquired company would have contributed SEK 0 million to the Group's net sales and SEK -3.4 to the Group's net profit.
Work on the purchase price allocation will be finally completed in the fourth quarter but according to the analysis carried out to date, most of the surplus value is attributable to ongoing research and development projects as well as a small amount attributable to goodwill. Deferred tax has been taken into account.
MetaboGen has a number of research and development projects currently underway. The company has made the assessment that when these are commercialized they will have a useful life of at least 10 years.
.
The effect on the Group's cash flow consists of the paid purchase consideration of SEK 11.7 million and acquired cash and cash equivalents of SEK 5.6 million. No other acquisition-related costs exist. During the third quarter BioGaia further acquired 30% of the company for SEK 27.8 million, which give a total effect on cashflow of SEK 33.9 million.
| Jan-Sept | Jan-Sept | Jan-Dec | |
|---|---|---|---|
| 2018 | 2017 | 2017 | |
| Opening balance | 463,888 | 415,180 | 415,180 |
| Remeasurement under IFRS 9 | -313 | - | - |
| Opening balance after remeasurement under IFRS 9 |
463,575 | 415,180 | 415,180 |
| Dividend | -156,028 | -130,023 | -130,023 |
| Provision to the Foundation to Prevent Antibiotic Formation of BioGaia Pharma |
-2,700 - |
- - |
-2,400 2 |
| Non-controlling interests related to the acquisition of MetaboGen Transaction between owners related to further |
17,062 | - | - |
| investment of shares in MetaboGen | -27,834 | - | - |
| Comprehensive income for the period | 157,008 | 133,066 | 181,129 |
| Closing balance | 451,083 | 418,223 | 463,888 |
| CONSOLIDATED KEY RATIOS | Jan-Sept | Jan-Sept | Jan-Dec |
|---|---|---|---|
| 2018 | 2017 | 2017 | |
| Net sales, SEK 000s | 532,197 | 444,855 | 615,003 |
| Growth, % | 20% | 10% | 15% |
| Operating profit, SEK 000s Profit after tax, SEK 000s Return on |
202,251 157,280 |
171,102 132,212 |
232,991 180,564 |
| - average equity | 35% | 32% | 41% |
| - average capital employed | 44% | 41% | 53% |
| Capital employed, SEK 000s | 458,716 | 418,555 | 464,666 |
| Number of shares, thousands 1) | 17,336 | 17,336 | 17,336 |
| Number of shares, thousands | 17,336 | 17,336 | 17,336 |
| Earnings per share, SEK 1) 2) | 9.10 | 7.63 | 10.42 |
| Equity per share, SEK 1) | 25.86 | 24.13 | 26.76 |
| Equity/assets ratio | 75% | 80% | 81% |
| Operating margin | 38% | 38% | 38% |
| Profit margin | 38% | 38% | 38% |
| Average number of employees | 125 | 113 | 115 |
1) No dilutive effects arose during the period
2) Key ratio defined according to IFRS
| Key ratios | Definition/Calculation | Purpose |
|---|---|---|
| Return on equity | Profit attributable to the owners of the Parent Company in relation to average equity attributable to the owners of the Parent Company. |
Return on equity is used to measure profit generation, over time, given the resources attributable to the owners of the Parent Company. |
| Return on capital employed | Profit before net financial items plus financial income as a percentage of average capital employed. |
Return on capital employed is used to analyze profitability, based on the amount of capital used. |
| Equity per share | Equity attributable to the owners of the Parent Company divided by the average number of shares. |
Equity per share measures the company's net value per share and indicates whether a company will increase the shareholders' wealth over time. |
| Operating profit (EBIT margin) | Operating profit expressed as a percentage of net sales. | The operating profit margin is used to measure operational profitability. |
| Equity/assets ratio | Equity at the end of the period as a percentage of total assets. | A traditional measure to show financial risk expressed as the share of total assets financed by the shareholders. Shows the company's stability and ability to withstand losses. |
| Capital employed | Total assets less interest-free liabilities. | Capital employed measures the total amount of investment needed to keep a company running and includes both equity and debt. |
| Growth | Sales for the current period less sales for the corresponding period of the previous year divided by sales for the previous period. |
Shows the company's realized sales growth over time. |
| Earnings per share (EPS) | Profit for the period attributable to the owners of the Parent Company divided by average number of shares outstanding (definition according to IFRS). |
EPS measures how much of net profit is available for payment to shareholders as dividends per share. |
| Profit margin | Profit before tax in relation to net sales. | This key ratio makes it possible to compare profitability regardless of corporate income tax rate. |
| Jan-Sept | Jan-Sept | Jan-Dec | |
|---|---|---|---|
| Return on equity | 2018 | 2017 | 2017 |
| Profit attributable to owners of the Parent Company (A) | 157,842 | 132,212 | 180,564 |
| Equity attributable to owners of the Parent Company | 447,849 | 418,239 | 463,904 |
| Average equity attributable to owners of the Parent Company (B) | 455,876 | 416,719 | 439,551 |
| Return on equity (A/B) | 35% | 32% | 41% |
| Jan-Sept | Jan-Sept | Jan-Dec | |
|---|---|---|---|
| Return on capital employed | 2018 | 2017 | 2017 |
| Operating profit Financial income |
202,251 274 |
171,102 - |
232,991 112 |
| Profit before financial items + financial income (A) Total assets Interest-free liabilities Capital employed Average capital employed (B) |
202,525 598,098 -139,382 458,716 461,691 |
171,102 522,830 -104,275 418,555 417,034 |
233,103 576,112 -111,446 464,666 440,089 |
| Return on capital employed (A/B) | 44% | 41% | 53% |
| 30 Sept | 30 Sept | 31 Dec | |
| Equity/assets ratio | 2018 | 2017 | 2017 |
| Equity (A) Total assets (B) |
451,083 598,098 |
418,223 522,830 |
463,888 576,112 |
| Equity/assets ratio (A/B) | 75% | 80% | 81% |
| Jan-Sept | Jan-Sept | Jan-Dec | |
| Operating margin | 2018 | 2017 | 2017 |
| Operating profit (A) Net sales (B) |
202,251 532,197 |
171,102 444,855 |
232,991 615,003 |
| Operating margin (A/B) | 38% | 38% | 38% |
Change in sales by segment (including and excluding foreign exchange effects)
| Adult | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pediatrics | Health | Other | Total | ||||||
| Jan-Sept | July-Sept | Jan-Sept | July-Sept | Jan-Sept | July-Sept | Jan-Sept | July-Sept | ||
| 2018 | 2018 | 2018 | 2018 | 2018 | 2018 | 2018 | 2018 | ||
| Description | |||||||||
| A | Previous year's net sales according to the average rate |
353,960 | 111,118 | 85,179 | 35,652 | 5,716 | 906 | 444,855 | 147,676 |
| B | Net sales for the year according to the average rate |
438,476 | 138,255 | 92,577 | 36,041 | 1,144 | 377 | 532,197 | 174,673 |
| C | Reported change (B-A) | 84,516 | 27,137 | 7,398 | 389 | -4,572 | -529 | 87,342 | 26,997 |
| Percentage change (C/A) | 24% | 24% | 9% | 1% | -80% | -58% | 20% | 18% | |
| D | Net sales for the year according to the previous year's average rate (D) |
426,803 | 128,220 | 89,230 | 33,200 | 1,144 | 377 | 517,177 | 161,797 |
| E | Foreign exchange effects (C-F) | 11,673 | 10,035 | 3,347 | 2,841 | 0 | 0 | 15,020 | 12,876 |
| Percentage change (E/A) | 3% | 9% | 4% | 8% | 0% | 0% | 3% | ||
| F | Organic change (D-A) | 72 843 | 17 102 | 4 051 | -2 452 | -4 572 | -529 | 72 322 | 14 121 |
| Organic change percent (F/A) | 21% | 15% | 5% | -7% | -80% | -58% | 16% | 10% |
| Average key exchange rates | Jan-Sept | July-Sept | Jan-Sept | July-Sept | Jan-Dec |
|---|---|---|---|---|---|
| 2018 | 2018 | 2017 | 2017 | 2017 | |
| EUR | 10.23 | 10.41 | 9.58 | 9.56 | 9.63 |
| USD | 8.58 | 8.95 | 8.61 | 8.14 | 8.54 |
| JPY | 7.82 | 8.03 | 7.69 | 7.33 | 7.61 |
| Key exchange rates on closing date | 30 Sept | 31 Dec | 30 Sept |
|---|---|---|---|
| 2018 | 2017 | 2017 | |
| EUR | 10.29 | 9.85 | 9.57 |
| USD | 8.86 | 8.23 | 8.11 |
| JPY | 7.81 | 7.31 | 7.21 |
Effects on assets, 1 January 2018
| IAS 39 Recognized at 31 Dec 2017 |
IFRS 9 Recognized at 1 Jan 2018 | ||||
|---|---|---|---|---|---|
| Category | Fair value through profit or loss |
Loans and trade receivables |
Remeasurement due to IFRS 9 |
Business model Other |
Business model Hold to Collect |
| Trade receivables 1) | 80,101 | -313 | 79,788 | ||
| Short-term investments 1) | 5,000 | 5,000 | |||
| Cash and cash equivalents 1) | 305,856 | 305,856 |
1) Hold to collect.
| 2017 according to Annual Report |
Reclassification | 2017 according to new accounting standard |
|
|---|---|---|---|
| Other operating expenses | -3,817 | -842 | -4,659 |
| Net financial items | -922 | 842 | -80 |
| Jan-Sept 2017 according to IAS 39 |
Reclassification | Jan-Sept 2017 according to new accounting standard |
|
| Other operating expenses | -6,456 | 1,983 | -4,473 |
| Net financial items | 1,829 | -1,983 | -154 |
| July-Sept 2017 according to IAS 39 |
Reclassification | July-Sept 2017 according to new accounting standard |
|
| Other operating expenses Net financial items |
-4,013 171 |
195 -195 |
-3,818 -24 |
| Jan-Sept 2018 according to IAS 39 |
Reclassification | Jan-Sept 2018 according to new accounting standard |
|
| Other operating income/expenses | 3,630 | -8,679 | -5,049 |
| Pledged assets and contingent liabilities | GROUP | PARENT COMPANY | ||
|---|---|---|---|---|
| 30 Sept | 31 Dec | 30 Sept | 31 Dec | |
| 2018 | 2017 | 2018 | 2017 | |
| Floating charges | 2,000 | 2,000 | 2,000 | 2,000 |
| Total | 2,000 | 2,000 | 2,000 | 2,000 |
| Contingent liabilities | None | None | None | None |
The Parent Company owns 100% of the shares in BioGaia Biologics Inc. USA, BioGaia Japan Inc, BioGaia Production AB and Tripac AB. The Parent Company also owns 90.1% of the shares in CapAble AB as well as 96% of the shares in BioGaia Pharma AB. With effect from 4 July 2018, BioGaia owns 92% of the former associated company MetaboGen AB (see above under Key Events in the Third Quarter).
Annwall & Rothschild Investment AB owns 740,668 class A shares and 509,332 class B shares which is equal to 7.2% of the share capital and 33% of the voting rights in BioGaia AB. Annwall & Rothschild Investment AB is owned by Peter Rothschild and Jan Annwall. Peter Rothschild is Chairman of the Board of BioGaia AB. The only transaction that took place during the period was the payment of a dividend of SEK 9.00 per share.
7 February 2019, 08:00 Year-end report 2018 March 2019 Annual Report 2018 8 August 2019, 08:00 Interim report 1 January – 30 June 2018
24 October 2018, 09:30 Teleconference with Acting Managing Director Sebastian Schröder. To participate in the teleconference, please see https://www.biogaia.com/investors/financial-calendar/ for telephone numbers. The teleconference can also be followed at https://tv.streamfabriken.com/biogaia-q3-2018. 8 May 2019, 08:00 Interim report 1 January – 31 March 2019 8 May 2019, 16:00 Annual General Meeting in Stockholm
Stockholm, 24 October 2018
Sebastian Schröder Acting Managing Director
This interim report has not been reviewed by the company's auditors.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Lactobacillus reuteri in combination with unique packaging solutions that make it possible to create probiotic products with a long shelf life.
The class B shares of the Parent Company BioGaia AB are quoted on the Mid Cap list of Nasdaq OMX Nordic Exchange Stockholm.
BioGaia has 127 employees, of whom 116 are based in Sweden (Stockholm, Lund and Eslöv), two in the USA, one in Singapore and eight in Japan.
BioGaia is working with three international networks within the areas of research, production and distribution.
BioGaia's revenue comes mainly from the sale of drops, gut health tablets, oral rehydration solution (ORS) and oral health products to distributors, but also of revenue from the sale of bacteria cultures to be used in licensee products (such as infant formula and dairy products), as well as royalty revenue for the use of Lactobacillus reuteri in licensee products and sales of delivery systems such as straws and caps.
The products are sold through nutrition and pharmaceutical companies in approximately 100 countries worldwide.
BioGaia holds patents for the use of Lactobacillus reuteri and certain packaging solutions in all major markets.
At the beginning of 2006 BioGaia launched its own consumer brand and today there are a number of distribution partners that sell finished products under the BioGaia brand in a large number of markets. One central part of BioGaia's strategy is to increase the share of sales consisting of BioGaia-branded products.
Some of BioGaia's distributors sell finished consumer products under their own brand names. On these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.
BioGaia's licensees add Lactobacillus reuteri culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.
BioGaia's strains of Lactobacillus reuteri are some of the world's most well researched probiotics, especially in young children. To date, 184 clinical studies using BioGaia's human strains of Lactobacillus reuteri have been performed on around 15,500 individuals of all ages. The results have been published in 159 articles in scientific journals.
Studies have been performed on:
BioGaia AB Box 3242, SE-103 64 STOCKHOLM Street address: Kungsbroplan 3A, Stockholm Telephone: +46 8-555 293 00, Corp, identity number, 556380-8723 www.biogaia.com For additional information, contact: Sebastian Schröder, Acting Managing Director, BioGaia AB, tel +46 8-555 293 00/+46 70-994 58 74
Margareta Hagman, Executive Vice President, BioGaia AB, tel +46 8-555 293 00/+46 708-72 82 33
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.